{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T01:14:41Z","timestamp":1711588481147},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,27]]},"DOI":"10.7759\/cureus.57063","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T19:14:24Z","timestamp":1711566864000},"source":"Crossref","is-referenced-by-count":0,"title":["Rehabilitation Outcomes in Multiple Sclerosis Patients on Ocrelizumab Diagnosed With West Nile Virus Encephalitis"],"prefix":"10.7759","author":[{"given":"Taylor R","family":"Johnson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Gandelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren R","family":"Serafin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy Y","family":"Charles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01672-9","article-title":"Ocrelizumab: a review in multiple sclerosis","volume":"82","author":"Lamb YN","year":"2022","unstructured":"Lamb YN. Ocrelizumab: a review in multiple sclerosis. Drugs. 2022, 82:323-34. 10.1007\/s40265-022-01672-9","journal-title":"Drugs"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci10100758","article-title":"Anti-CD20 agents for multiple sclerosis: spotlight on ocrelizumab and ofatumumab","volume":"10","author":"Florou D","year":"2020","unstructured":"Florou D, Katsara M, Feehan J, Dardiotis E, Apostolopoulos V. Anti-CD20 agents for multiple sclerosis: spotlight on ocrelizumab and ofatumumab. Brain Sci. 2020, 10:4-6. 10.3390\/brainsci10100758","journal-title":"Brain Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9010012","article-title":"Safety of newer disease-modifying therapies in multiple sclerosis","volume":"9","author":"Jalkh G","year":"2020","unstructured":"Jalkh G, Abi Nahed R, Macaron G, Rensel M. Safety of newer disease-modifying therapies in multiple sclerosis. Vaccines (Basel). 2020, 9:24-6. 10.3390\/vaccines9010012","journal-title":"Vaccines (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01252-5","article-title":"Does ocrelizumab limit multiple sclerosis progression? Current evidence from clinical, MRI, and fluid biomarkers","volume":"19","author":"Margoni M","year":"2022","unstructured":"Margoni M, Preziosa P, Tortorella P, Filippi M, Rocca MA. Does ocrelizumab limit multiple sclerosis progression? Current evidence from clinical, MRI, and fluid biomarkers. Neurotherapeutics. 2022, 19:1216-28. 10.1007\/s13311-022-01252-5","journal-title":"Neurotherapeutics"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012700","article-title":"Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis","volume":"97","author":"Hauser SL","year":"2021","unstructured":"Hauser SL, Kappos L, Montalban X, et al.. Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis. Neurology. 2021, 97:e1546-59. 10.1212\/WNL.0000000000012700","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2022.60","article-title":"B-cell-directed therapies: a new era in multiple sclerosis treatment","volume":"50","author":"Kanatas P","year":"2023","unstructured":"Kanatas P, Stouras I, Stefanis L, Stathopoulos P. B-cell-directed therapies: a new era in multiple sclerosis treatment. Can J Neurol Sci. 2023, 50:355-64. 10.1017\/cjn.2022.60","journal-title":"Can J Neurol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8040748","article-title":"The roles of Osteopontin in the pathogenesis of West Nile encephalitis","volume":"8","author":"Nazneen F","year":"2020","unstructured":"Nazneen F, Bai F. The roles of Osteopontin in the pathogenesis of West Nile encephalitis. Vaccines (Basel). 2020, 8:2-4. 10.3390\/vaccines8040748","journal-title":"Vaccines (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11101253","article-title":"Rehabilitation outcomes in subjects with West Nile neuro-invasive disease","volume":"11","author":"Patel K","year":"2021","unstructured":"Patel K, Greenwald BD, Sabini RC. Rehabilitation outcomes in subjects with West Nile neuro-invasive disease. Brain Sci. 2021, 11:42-4. 10.3390\/brainsci11101253","journal-title":"Brain Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2012.00037","article-title":"Neuromuscular manifestations of West Nile virus infection","volume":"3","author":"Leis AA","year":"2012","unstructured":"Leis AA, Stokic DS. Neuromuscular manifestations of West Nile virus infection. Front Neurol. 2012, 3:37. 10.3389\/fneur.2012.00037","journal-title":"Front Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031223","article-title":"A critical role for induced IgM in the protection against West Nile virus infection","volume":"198","author":"Diamond MS","year":"2003","unstructured":"Diamond MS, Sitati EM, Friend LD, Higgs S, Shrestha B, Engle M. A critical role for induced IgM in the protection against West Nile virus infection. J Exp Med. 2003, 198:1853-62. 10.1084\/jem.20031223","journal-title":"J Exp Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s13365-020-00854-z","article-title":"West Nile virus neuroinvasive disease associated with rituximab therapy","volume":"26","author":"Owens M","year":"2020","unstructured":"Owens M, Choe L, Rivera JE, Avila JD. West Nile virus neuroinvasive disease associated with rituximab therapy. J Neurovirol. 2020, 26:611-4. 10.1007\/s13365-020-00854-z","journal-title":"J Neurovirol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200154","article-title":"Severe neuroinvasive West Nile virus in association with anti-CD20 monotherapy for multiple sclerosis","volume":"10","author":"Thebault S","year":"2023","unstructured":"Thebault S, Gandelman S, Lane C, et al.. Severe neuroinvasive West Nile virus in association with anti-CD20 monotherapy for multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023, 10:3-5. 10.1212\/NXI.0000000000200154","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2004.10.019","article-title":"Rehabilitation outcomes of 5 patients with severe West Nile virus infection: a case series","volume":"86","author":"Rao N","year":"2005","unstructured":"Rao N, Char D, Gnatz S. Rehabilitation outcomes of 5 patients with severe West Nile virus infection: a case series. Arch Phys Med Rehabil. 2005, 86:449-52. 10.1016\/j.apmr.2004.10.019","journal-title":"Arch Phys Med Rehabil"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012732.pub2","article-title":"Rehabilitation for people with multiple sclerosis: an overview of Cochrane Reviews","volume":"1","author":"Amatya B","year":"2019","unstructured":"Amatya B, Khan F, Galea M. Rehabilitation for people with multiple sclerosis: an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2019, 1:CD012732. 10.1002\/14651858.CD012732.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref15","article-title":"Prognostic factors in multiple sclerosis rehabilitation","volume":"45","author":"Grasso MG","year":"2009","unstructured":"Grasso MG, Pace L, Troisi E, Tonini A, Paolucci S. Prognostic factors in multiple sclerosis rehabilitation. Eur J Phys Rehabil Med. 2009, 45:47-51.","journal-title":"Eur J Phys Rehabil Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3233\/NRE-2012-0731","article-title":"Outcomes of inpatient rehabilitation of patients with multiple sclerosis","volume":"30","author":"Gaber TA","year":"2012","unstructured":"Gaber TA, Oo WW, Gautam V, Smith L. Outcomes of inpatient rehabilitation of patients with multiple sclerosis. NeuroRehabilitation. 2012, 30:97-100. 10.3233\/NRE-2012-0731","journal-title":"NeuroRehabilitation"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3233\/NRE-130956","article-title":"Benefits of inpatient multidisciplinary rehabilitation in multiple sclerosis","volume":"33","author":"Salhofer-Polanyi S","year":"2013","unstructured":"Salhofer-Polanyi S, Windt J, Sumper H, et al.. Benefits of inpatient multidisciplinary rehabilitation in multiple sclerosis. NeuroRehabilitation. 2013, 33:285-92. 10.3233\/NRE-130956","journal-title":"NeuroRehabilitation"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/2055217321989384","article-title":"Personalised inpatient multidisciplinary rehabilitation elicits clinically relevant improvements in physical function in patients with multiple sclerosis - the Danish MS Hospitals Rehabilitation Study","volume":"7","author":"Hvid LG","year":"2021","unstructured":"Hvid LG, Gaemelke T, Dalgas U, et al.. Personalised inpatient multidisciplinary rehabilitation elicits clinically relevant improvements in physical function in patients with multiple sclerosis - the Danish MS Hospitals Rehabilitation Study. Mult Scler J Exp Transl Clin. 2021, 7:2055217321989384. 10.1177\/2055217321989384","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/j.2048-7940.1988.tb00634.x","article-title":"Multiple sclerosis rehabilitation: inpatient vs. outpatient","volume":"13","author":"Francabandera FL","year":"1988","unstructured":"Francabandera FL, Holland NJ, Wiesel-Levison P, Scheinberg LC. Multiple sclerosis rehabilitation: inpatient vs. outpatient. Rehabil Nurs. 1988, 13:251-3. 10.1002\/j.2048-7940.1988.tb00634.x","journal-title":"Rehabil Nurs"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1177\/2055217319843673","article-title":"Predictors of hospital-based multidisciplinary rehabilitation effects in persons with multiple sclerosis: a large-scale, single-centre study","volume":"5","author":"Groppo E","year":"2019","unstructured":"Groppo E, Signori A, Sormani MP, Grosso C, Mantia L, Cattaneo D, Rovaris M. Predictors of hospital-based multidisciplinary rehabilitation effects in persons with multiple sclerosis: a large-scale, single-centre study. Mult Scler J Exp Transl Clin. 2019, 5:2055217319843673. 10.1177\/2055217319843673","journal-title":"Mult Scler J Exp Transl Clin"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/233179-rehabilitation-outcomes-in-multiple-sclerosis-patients-on-ocrelizumab-diagnosed-with-west-nile-virus-encephalitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T19:14:39Z","timestamp":1711566879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/233179-rehabilitation-outcomes-in-multiple-sclerosis-patients-on-ocrelizumab-diagnosed-with-west-nile-virus-encephalitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.57063","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,27]]}}}